<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets</h1>

    <table>
      <tr><th>Ticker</th><td>TPST</td></tr>
      <tr><th>Float</th><td>4.6 M</td></tr>
      <tr><th>IO</th><td>15.92%</td></tr>
      <tr><th>MC</th><td>31.3 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Tempest Therapeutics (NASDAQ: TPST) announced a capital-efficient post-transaction plan to advance its newly acquired CAR-T portfolio by prioritizing partner-funded and externally supported development. Near-term focus is on TPST-2003, a dual-targeting CD19/BCMA CAR-T with ongoing Phase 1 data expected from China, and a registrational Phase 2b in China targeted by end of 2026 with interim data in 2027 (China development funded by a strategic partner). Tempest disclosed TPST-4003, an in vivo CD19/BCMA program intended to be advanced via preclinical work and a potential partner-funded investigator-initiated trial. The company intends to pursue business development for amezalpat (Phase 3-ready in first-line HCC) and to advance TPST-1495 into a Phase 2 FAP study expected to enroll first patient in Q1 2026 (anticipated NCI funding). Additional next-generation programs (allogeneic and CD70-targeting constructs) are planned. The release reiterates standard forward-looking risks including need for additional capital, uncertainty of partner or NCI funding, clinical and regulatory risks, and possible operational or enrollment delays.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Capital-efficient strategy emphasizing partner-funded and externally supported development to conserve internal capital.</li><li>Near-term clinical milestones: ongoing Phase 1 data for TPST-2003 and planned registrational Phase 2b in China (targeted by end of 2026; interim data 2027).</li><li>Pipeline expansion with TPST-4003 (in vivo CD19/BCMA) to potentially improve scalability and patient convenience.</li><li>TPST-1495 Phase 2 in FAP expected to be funded by the National Cancer Institute, reducing internal cash burden.</li><li>Amezalpat is positioned as Phase 3-ready in first-line hepatocellular carcinoma, supporting business-development pathways.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Company acknowledges need for additional capital and that its ability to continue programs depends on funding availability.</li><li>Planned partner or NCI funding may not materialize on expected timelines or at anticipated levels.</li><li>Development timelines are forward-looking and subject to clinical, regulatory, enrollment and operational risks.</li><li>Outcomes depend on safety/efficacy data; negative or unexpected results could materially alter plans.</li><li>Reliance on external partners reduces direct control over certain pivotal development activities.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/73ca1615-7204-48dd-b5e7-36fb8370e376" target="_blank">Original Article</a>
    </div>

    <div class="small">TPST â€¢ TradersLink AI News</div>
  </div>
</body>
</html>